Company: MDCXW
Filing Date: 2025-06-30
Form Type: DEF 14A
Source: 0001062993-25-012273
Chunk: 1

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-30
Form: DEF 14A
Chunk 1
---
 First Canadian Place, Toronto, Ontario, Canada M5X 1A4.

The following matters will be considered at the Meeting:

| 1. | the receipt of the audited financial statements of the Company for the financial years ended December 2024 and 2023, together with the auditor's reports thereon;                                                                                                                                                                                                                                          |
| 2. | the appointment of KPMG LLP as auditors for the Company and the authorization of the board of directors of the Company (the "Board") to fix the auditors' remuneration and terms of engagement;                                                                                                                                                                                                            |
| 3. | the election of the directors for the forthcoming year from the nominees proposed by the Board;                                                                                                                                                                                                                                                                                                            |
| 4. | the confirmation and approval of an amendment to the Company's by-laws to increase the quorum requirement for the transaction of business at a meeting of shareholders as described in the accompanying proxy statement;                                                                                                                                                                                   |
| 5. | the approval in accordance with Nasdaq Rule 5635(d) (the "Nasdaq 20% Rule") of the issuance of Common Shares pursuant to the Standby Equity Purchase Agreement, dated February 10, 2025 between the Company and YA II PN, Ltd., which may exceed 20% or more of the Common Shares outstanding at the applicable time and be at a price per share below the minimum price specified by the Nasdaq 20% Rule; |
| 6. | a special resolution approving an amendment to the Company's articles of incorporation as described in the accompanying proxy statement; and                                                                                                                                                                                                                                                               |
| 7. | the transaction of such other business as may properly come before the Meeting or any adjournment(s) or postponement(s) thereof.                                                                                                                                                                                                                                                                           |

This Notice is accompanied by: (1) the proxy statement; (2) the proxy card ("Proxy Card"); and (3) the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (including the audited annual consolidated financial statements of the Company for the fiscal year ended December 31, 2024, together with the notes thereto, and the independent auditor's report thereon and the related management's discussion and analysis) (collectively, the "Proxy Materials"). The Company is not sending the Proxy Materials to registered Shareholders or non-registered Shareholders using notice-and-access delivery procedures under the rules of the U.S. Securities and Exchange Commission and as defined under National Instrument 54-